APLS vs DOCU · rev $781.4M vs P/E 15, rev $1.71B
Apellis Pharmaceuticals Inc (APLS) versus DocuSign Inc (DOCU) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
DocuSign Inc (DOCU) is a software - application company listed on US.
Latest reported APLS revenue for 2024-12-31 was $781.4M. Net income was -$197.9M. Revenue was up 97.0% from 2023-12-31 to 2024-12-31. APLS currently screens at market cap $2.29B.
Latest reported DOCU revenue for 2026-07-31 was $1.71B. Net income was $155.9M. DOCU currently screens at market cap $15.74B and trailing P/E 14.8.
APLS currently screens at market cap $2.29B. DOCU currently screens at market cap $15.74B and trailing P/E 14.8.
Not investment advice. Open the APLS and DOCU stock pages for the full models.
Not investment advice.